AP478A - Use of triazine compounds for the treatment of impaired memory and learning disorders. - Google Patents
Use of triazine compounds for the treatment of impaired memory and learning disorders. Download PDFInfo
- Publication number
- AP478A AP478A APAP/P/1994/000627A AP9400627A AP478A AP 478 A AP478 A AP 478A AP 9400627 A AP9400627 A AP 9400627A AP 478 A AP478 A AP 478A
- Authority
- AP
- ARIPO
- Prior art keywords
- impaired memory
- learning disorder
- pharmaceutically
- treatment
- dichlorophenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939305693A GB9305693D0 (en) | 1993-03-19 | 1993-03-19 | Therapeutic triazine compounds and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9400627A0 AP9400627A0 (en) | 1994-04-30 |
| AP478A true AP478A (en) | 1996-03-08 |
Family
ID=10732358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1994/000627A AP478A (en) | 1993-03-19 | 1994-03-18 | Use of triazine compounds for the treatment of impaired memory and learning disorders. |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9424766D0 (en) * | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
| DE19603984A1 (de) * | 1996-02-05 | 1997-08-07 | Bayer Ag | Granulate von Triazinen |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0021121A1 (en) * | 1979-06-01 | 1981-01-07 | The Wellcome Foundation Limited | 1,2,4-Triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them |
| EP0247892A1 (en) * | 1986-05-30 | 1987-12-02 | The Wellcome Foundation Limited | Triazine salt |
| EP0519602A1 (en) * | 1991-05-21 | 1992-12-23 | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. | Use of a dihydrothienopyridine-derivative for inhibiting the release of cerebral glutamate |
-
1993
- 1993-03-19 GB GB939305693A patent/GB9305693D0/en active Pending
-
1994
- 1994-03-18 AP APAP/P/1994/000627A patent/AP478A/en active
- 1994-03-18 JP JP6520807A patent/JPH08507782A/ja not_active Ceased
- 1994-03-18 PT PT94909263T patent/PT689439E/pt unknown
- 1994-03-18 TW TW083102373A patent/TW256773B/zh active
- 1994-03-18 IL IL10903494A patent/IL109034A/en active IP Right Grant
- 1994-03-18 DK DK94909263T patent/DK0689439T3/da active
- 1994-03-18 AT AT94909263T patent/ATE198831T1/de not_active IP Right Cessation
- 1994-03-18 WO PCT/GB1994/000559 patent/WO1994021260A1/en active IP Right Grant
- 1994-03-18 ZA ZA941938A patent/ZA941938B/xx unknown
- 1994-03-18 EP EP94909263A patent/EP0689439B1/en not_active Expired - Lifetime
- 1994-03-18 AU AU62176/94A patent/AU6217694A/en not_active Abandoned
- 1994-03-18 ES ES94909263T patent/ES2153854T3/es not_active Expired - Lifetime
- 1994-03-18 DE DE69426622T patent/DE69426622T2/de not_active Expired - Fee Related
-
2001
- 2001-03-08 GR GR20010400367T patent/GR3035528T3/el not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0021121A1 (en) * | 1979-06-01 | 1981-01-07 | The Wellcome Foundation Limited | 1,2,4-Triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them |
| EP0247892A1 (en) * | 1986-05-30 | 1987-12-02 | The Wellcome Foundation Limited | Triazine salt |
| EP0519602A1 (en) * | 1991-05-21 | 1992-12-23 | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. | Use of a dihydrothienopyridine-derivative for inhibiting the release of cerebral glutamate |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9305693D0 (en) | 1993-05-05 |
| PT689439E (pt) | 2001-05-31 |
| DE69426622T2 (de) | 2001-06-21 |
| TW256773B (enrdf_load_html_response) | 1995-09-11 |
| DE69426622D1 (de) | 2001-03-01 |
| IL109034A0 (en) | 1994-06-24 |
| ES2153854T3 (es) | 2001-03-16 |
| ZA941938B (en) | 1995-09-18 |
| ATE198831T1 (de) | 2001-02-15 |
| EP0689439B1 (en) | 2001-01-24 |
| WO1994021260A1 (en) | 1994-09-29 |
| JPH08507782A (ja) | 1996-08-20 |
| AP9400627A0 (en) | 1994-04-30 |
| GR3035528T3 (en) | 2001-06-29 |
| DK0689439T3 (da) | 2001-04-17 |
| EP0689439A1 (en) | 1996-01-03 |
| IL109034A (en) | 1998-12-06 |
| AU6217694A (en) | 1994-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU622630B2 (en) | D-cycloserine and its prodrugs as cognitive enhancers | |
| EP0387867B1 (en) | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder | |
| US5034400A (en) | Method for preventing neurotoxic side effects of NMDA antagonists | |
| US20060241144A1 (en) | Method for treating apathy syndrome | |
| WO2014133182A1 (ja) | 眼炎症性疾患の予防及び／または治療剤 | |
| US5866597A (en) | Use of triazine compounds for the treatment of memory and learning disorders | |
| AP478A (en) | Use of triazine compounds for the treatment of impaired memory and learning disorders. | |
| AU606531B2 (en) | Method of ameliorating epileptic seizures | |
| US6420404B2 (en) | Use of amino-isoxazolidone compounds for improvement of implicit memory | |
| US6399650B2 (en) | Method for improving disturbancies of activities of daily living after stroke | |
| US5087633A (en) | Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder | |
| US5468763A (en) | Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder | |
| US6962921B2 (en) | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | |
| US20020045565A1 (en) | Method for treating or preventing emesis | |
| BG63378B1 (bg) | Използване на 1-ар(алк)ил-имидазолин-2-он за лечение на страхови и стресови състояния | |
| GB2240476A (en) | Use of 5HT-3 antagonist for preventing or reducing dependence | |
| IE913211A1 (en) | Use of n-(1-hexahydroazepinylalkyl) acetamides in the¹preparation of medicaments for the treatment of cholinergic¹transmission disorders |